Our Pricing

Mounjaro Dose Timeline: What Happens Week by Week

Understanding the mounjaro dose timeline UK protocol is essential for patients starting tirzepatide treatment. At Cured Pharmacy, our UK prescribers follow MHRA-approved dosing schedules, beginning at 2.5mg weekly and gradually escalating to optimise weight loss whilst minimising side effects. This week-by-week guide explains exactly what to expect during each phase of your Mounjaro journey.

Understanding the Mounjaro Dose Timeline UK Protocol

Mounjaro follows a structured dose escalation schedule designed to improve tolerability whilst maximising clinical outcomes. The UK-licensed protocol begins with a 2.5mg subcutaneous injection once weekly for four weeks, serving as an initiation dose that allows your body to adapt to tirzepatide's dual GIP/GLP-1 receptor activation [1].

After the initial four-week period, your UK prescriber will typically increase your dose to 5mg weekly for another four weeks, provided you're tolerating the medication well. This gradual titration approach, validated in the SURPASS clinical trial programme, reduces the incidence of gastrointestinal side effects compared to starting at higher doses [1][2].

The maximum maintenance dose is 15mg weekly, though many patients achieve their weight loss goals at lower doses. Your prescriber will determine the optimal maintenance dose based on your response, tolerability, and clinical objectives during your regular review consultations.

Weeks 1-4: Starting Dose (2.5mg Weekly)

During your first month on Mounjaro, you'll inject 2.5mg once weekly on the same day each week. This initiation phase primes your body's GIP and GLP-1 receptors, beginning to regulate appetite signals and glucose metabolism [1].

Most patients notice reduced hunger and earlier satiety within the first two weeks, though significant weight loss typically begins in weeks three to four. In clinical trials, patients lost an average of 2-3% body weight during the 2.5mg phase, with minimal side effects when following proper injection technique [2].

Common experiences during weeks 1-4 include mild nausea (typically subsiding after meals), reduced food cravings, and improved portion control. These effects indicate the medication is working as intended. Staying well-hydrated and eating smaller, more frequent meals can help minimise any digestive discomfort.

What to Expect in Your First Injection

Your first Mounjaro injection should be administered subcutaneously into your abdomen, thigh, or upper arm using the pre-filled KwikPen. The 2.5mg dose is specifically designed as a starter dose, so you may not feel dramatic effects immediately—this is normal and expected.

Rotate injection sites weekly to prevent lipohypertrophy (skin thickening). Mark your calendar for the same day each week to maintain consistent therapeutic levels. If you miss a dose by more than four days, contact your prescriber before administering the next injection.

Weeks 5-8: First Dose Increase (5mg Weekly)

After completing four weeks at 2.5mg, your UK prescriber will typically escalate your dose to 5mg weekly, provided you've tolerated the initiation dose well. This represents the first therapeutic dose increase in the standard Mounjaro titration schedule.

The 5mg dose produces more pronounced appetite suppression and metabolic effects. In the SURPASS-1 trial, patients on 5mg tirzepatide achieved an average 7.6% body weight reduction over 40 weeks [1]. You may notice increased satiety between meals and reduced interest in high-calorie foods during this phase.

Some patients experience a temporary increase in gastrointestinal side effects (nausea, mild diarrhoea) during the first week at 5mg as their body adjusts to the higher dose. These symptoms typically resolve within 7-10 days. If side effects persist or worsen, consult your prescriber before your next scheduled dose increase.

Weeks 9-12: Second Dose Increase (7.5mg Weekly)

Following four weeks at 5mg, the standard protocol progresses to 7.5mg weekly. This intermediate dose represents a significant step in the titration pathway, bridging the gap between initial therapeutic doses and higher maintenance levels.

Clinical data shows that 7.5mg tirzepatide produces substantial weight loss outcomes, with many patients achieving 10-12% body weight reduction by this stage of treatment [2]. The dual receptor mechanism becomes increasingly evident, with improvements in both glycaemic control and appetite regulation.

Your UK prescriber may choose to maintain you at 7.5mg as your long-term maintenance dose if you're achieving satisfactory weight loss with good tolerability. Not all patients require escalation to higher doses—treatment is individualised based on your response and clinical goals.

Assessing Your Progress at 12 Weeks

The 12-week mark represents an important milestone in Mounjaro treatment. Your prescriber will review your weight loss progress, tolerability, and overall response to determine whether further dose escalation is appropriate or whether 7.5mg should remain your maintenance dose.

NICE guidelines suggest that weight loss treatments should demonstrate at least 5% body weight reduction by 12 weeks to justify continuation. Most patients on Mounjaro exceed this threshold significantly, with average reductions of 8-12% at the 7.5mg dose level [1][2].

Weeks 13-16: Third Dose Increase (10mg Weekly)

For patients requiring additional weight loss or those who tolerated 7.5mg well without reaching their clinical targets, escalation to 10mg weekly occurs after week 12. The 10mg dose represents a higher therapeutic tier within the Mounjaro dosing schedule.

In the SURPASS-3 trial, participants on 10mg tirzepatide achieved an average 19.5% body weight reduction over 72 weeks—substantially higher than comparator treatments [1]. This dose level provides robust appetite suppression whilst maintaining acceptable tolerability in most patients.

At 10mg, you may notice plateau periods where weight loss slows temporarily before resuming. This is physiologically normal as your body adapts to its new metabolic set point. Maintaining consistent dosing, adequate hydration, and a balanced diet supports continued progress through these phases.

Weeks 17+: Maximum Dose and Maintenance (12.5mg-15mg Weekly)

The highest licensed doses—12.5mg and 15mg weekly—are reserved for patients who tolerate lower doses well but require additional therapeutic effect to reach their weight loss goals. The 15mg dose represents the maximum approved strength in the UK under current MHRA licensing [3].

Clinical trial data demonstrates that 15mg tirzepatide produces the greatest weight loss outcomes, with participants achieving an average 22.5% body weight reduction over 72 weeks in SURPASS-3 [1]. However, higher doses also carry increased risk of gastrointestinal side effects, requiring careful clinical assessment before escalation.

Once you reach your maintenance dose—whether that's 7.5mg, 10mg, 12.5mg, or 15mg—you'll continue at that level for the duration of your treatment. Regular follow-up consultations with your UK prescriber ensure ongoing monitoring of efficacy, tolerability, and any necessary dose adjustments. At Cured Pharmacy, Mounjaro is available from £135.00 per month, with transparent pricing provided before your clinical assessment.

Long-Term Maintenance and Monitoring

Maintenance therapy with Mounjaro requires ongoing clinical supervision to monitor weight loss progress, manage any side effects, and assess for potential dose adjustments. Your UK prescriber will schedule regular review consultations—typically every 12 weeks—to ensure treatment remains appropriate and effective.

Some patients may require dose reduction if they experience persistent side effects or achieve significant weight loss that makes lower doses sufficient. Others may benefit from temporary treatment breaks once they've reached their target weight, though this should only be done under prescriber guidance to prevent weight regain.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
2. Ludvik, B., Giorgino, F., Jódar, E., et al. (2021). Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. The Lancet, 398(10300), 583–598. https://doi.org/10.1016/S0140-6736(21)01443-4
3. Medicines and Healthcare products Regulatory Agency. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen: Summary of Product Characteristics. GOV.UK. https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary. Weight loss outcomes cited from clinical trials represent average results and are not guaranteed for any individual patient.